Suven Life Sciences Limited

Suven Life Sciences Limited

Suven Life Sciences Limited has allotted 2,71,970 equity shares under its SLSL ESOP 2020 Scheme to eligible employees. The shares were issued at an exercise price of Rs. 55 each, leading to a capital inflow of approximately Rs. 1.49 crore. Following this allotment, the company's paid-up equity share capital increased from 26,37,20,583 shares to 26,39,92,553 shares. This is a procedural update regarding employee stock option exercise.

Suven Life Sciences Limited

Suven Life Sciences announced its participation in the BIO International Convention 2026 to showcase its differentiated Central Nervous System (CNS) clinical candidates. The company aims to explore strategic partnering, out-licensing, and co-development initiatives for its late-stage clinical assets, including Masupirdine and Samelisant (both in Phase 3) and Ropanicant, which recently reported positive Phase 2b results. Senior management will engage in numerous pre-scheduled meetings with global pharmaceutical and biotechnology companies.